What evaluations and management should be recommended for a 38‑year‑old woman with a five‑year history of urinary frequency, intermittent shakiness and weakness, dry eyes, cold extremities, coarse chin hair, leukocytosis, hypoglycemia, vitamin D deficiency, borderline thyroid antibodies, elevated DHEA and mild hyperandrogenism?

Comprehensive Endocrine and Urologic Evaluation with Targeted Treatment for Hyperandrogenism

This patient requires immediate comprehensive evaluation for hyperandrogenism with elevated DHEA (392) and testosterone (38, Free T 2.3), focusing on determining the source of androgen excess (adrenal vs. ovarian) through dynamic testing, while simultaneously addressing urinary frequency with urologic assessment and correcting vitamin D deficiency.

Primary Diagnostic Priorities

1. Hyperandrogenism Workup (Most Critical)

The constellation of coarse chin hair, elevated DHEA, and elevated testosterone indicates significant hyperandrogenism requiring urgent evaluation 1. The diagnostic evaluation must determine the specific androgens involved, degree of hypersecretion, organs of origin (ovaries vs. adrenal glands), and whether excess production is due to organ dysfunction, hyperplasia, or neoplasm 1.

Essential laboratory testing:

• Morning fasting testosterone, free testosterone, and DHEAS levels to confirm hyperandrogenemia 1
• 17-hydroxyprogesterone to evaluate for non-classic congenital adrenal hyperplasia
• Fasting glucose and insulin to calculate glucose/insulin ratio (ratio <4.5 indicates insulin resistance) 1
• Lipid panel (HDL cholesterol and triglycerides) as hyperandrogenism increases cardiovascular risk 1
• Dynamic suppression testing: Dexamethasone suppression test to determine if hyperandrogenism is glucocorticoid-suppressible (adrenal origin) 1

Imaging:

• Pelvic ultrasound to evaluate for polycystic ovaries, ovarian tumors, or hyperthecosis 1
• Adrenal imaging if DHEA remains markedly elevated or if adrenal tumor is suspected

2. Metabolic Assessment

The random glucose of 67 mg/dL with shakiness/weakness 3x/week (mid-morning/early afternoon) suggests reactive hypoglycemia, which can occur in the context of insulin resistance paradoxically 1. The A1C of 5.0 is reassuring but doesn't exclude insulin resistance.

Required testing:

• Oral glucose tolerance test with insulin levels at 0,30,60,90, and 120 minutes to assess total integrated insulin response 1
• This is superior to simple fasting measurements for detecting insulin resistance in hyperandrogenic patients

3. Urinary Frequency Evaluation

Five years of urinary frequency requires systematic urologic assessment 2:

Step-wise evaluation:

• 3-day voiding diary documenting frequency, volume, and timing patterns
• Postvoid residual measurement via ultrasound to assess voiding efficiency
• Urinalysis and urine culture to definitively rule out chronic/recurrent infection (though WBC elevation may be unrelated)
• Physical examination for pelvic organ prolapse, pelvic floor trigger points requiring myofascial therapy 2

Important consideration: Subclinical thyroid dysfunction can present with urinary frequency 3, though your thyroid panel is optimal. The borderline TPO antibodies (11) warrant monitoring but don't explain current symptoms.

4. Additional Evaluations

• Vitamin D supplementation is immediately indicated given documented deficiency and association with autoimmune thyroid disease progression 4, 5, 6
• Dry eyes: Evaluate for Sjögren's syndrome with anti-SSA/SSB antibodies given autoimmune context (rising TPO)
• Cold extremities: Check for Raynaud's phenomenon; consider rheumatologic evaluation if other autoimmune features present
• Elevated WBC/neutrophils: Requires follow-up CBC to determine if persistent; consider inflammatory vs. infectious etiology

Treatment Algorithm Based on Diagnostic Results

If Predominantly Adrenal Hyperandrogenism (Glucocorticoid-Suppressible):

First-line therapy: Low-dose glucocorticoids 1

• Prednisone 5-7.5 mg daily after supper OR Dexamethasone 0.25-0.5 mg daily for 2-3 months
• Reassess androgen levels; if normalized, taper to prednisone 5 mg or dexamethasone 0.25 mg for 2-3 months
• Further taper or discontinue; monitor androgens every 3-4 months for 1 year 1
• Benefits: Sustained amelioration of hirsutism, improved ovulatory function, addresses metabolic complications 1
• Note: Prednisone preferred over dexamethasone for long-term use due to lower metabolic risks 1

If Combined or Predominantly Ovarian Hyperandrogenism:

Combination therapy 1:

• Oral contraceptives (combined hormonal contraceptives) to suppress ovarian androgens PLUS
• Spironolactone 50-200 mg daily (antiandrogen) for hirsutism
• Metformin 1500-2000 mg daily if insulin resistance confirmed (glucose/insulin ratio <4.5) 1

Alternative if insulin resistance with obesity/metabolic syndrome:

• Metformin as primary therapy with lifestyle modification (weight loss target: 7% body weight) 1
• Weight loss alone can restore ovulation, decrease androgens, increase SHBG 1

For Urinary Frequency (Concurrent Management):

Based on voiding diary and examination findings 2:

• Behavioral therapy: Timed voiding, bladder training
• Pelvic floor physical therapy if trigger points identified
• Anticholinergic medications (oxybutynin, tolterodine) if overactive bladder confirmed
• Avoid empiric treatment without proper evaluation

Immediate Interventions (Start Now):

1. Vitamin D3 supplementation: 2000-4000 IU daily to achieve levels >30 ng/mL 4, 5
2. Dietary counseling: Small, frequent meals with complex carbohydrates to manage reactive hypoglycemia
3. Weight management if BMI elevated (not specified but common in hyperandrogenism)

Critical Pitfalls to Avoid

• Do not treat hirsutism symptomatically without determining androgen source - this delays diagnosis of potentially serious conditions (adrenal/ovarian tumors) 1
• Do not assume urinary frequency is solely urologic - endocrine disorders (hyperthyroidism, diabetes insipidus) must be excluded 3
• Do not overlook cardiovascular risk - hyperandrogenism with insulin resistance significantly increases risk for hypertension, dyslipidemia, and type 2 diabetes 1
• Early intervention is crucial - untreated hyperandrogenism leads to progressive metabolic complications, infertility, and cardiovascular disease 1

Follow-Up Timeline

• 2-3 months: Reassess androgen levels, metabolic parameters, symptom improvement
• 6 months: Repeat lipid panel, glucose tolerance test if initially abnormal
• Every 3-4 months for 1 year: Monitor for recurrence of hyperandrogenemia after treatment taper 1
• Annual: Thyroid function and TPO antibodies given borderline elevation

The goal is androgen normalization within 2-3 months, which should improve hirsutism, restore metabolic function, and potentially address systemic symptoms 1. The leukocytosis requires separate investigation if persistent on repeat testing.